assess
specif
cytotox
lymphocyt
ctl
sever
acut
respiratori
syndrom
sar
coronaviru
modifi
dimerx
flow
cytometri
assay
perform
peripher
blood
mononuclear
cell
pbmc
sarsrecov
donor
differ
time
point
post
diseas
ctl
detect
pbmc
donor
month
recoveri
percentag
cell
parallel
number
interferongposit
spot
elispot
assay
use
antigen
peptid
conclus
dimerxbas
flow
cytometri
stain
may
prove
realtim
method
screen
ctl
direct
epitop
newli
identifi
viru
sever
acut
respiratori
syndrom
sar
newli
describ
viral
diseas
first
appear
within
past
year
pathogen
agent
sar
coronaviru
sarscov
repres
new
strain
coronaviru
date
effect
treatment
current
involv
support
therapi
presum
antivir
immun
respons
develop
appear
consist
neutral
ab
well
cytotox
lymphocyt
ctl
detect
sar
infect
previous
shown
nonapeptid
correspond
sequenc
protein
sarscov
could
induc
interferongproduc
lymphocyt
use
elispot
assay
dimerx
ig
fusion
proteinpeptid
complex
stain
evalu
via
flow
cytometri
shown
ctl
specif
viral
epitop
studi
present
evid
presenc
ofantisarscovspecif
cell
peripher
blood
mononuclear
cell
pbmc
obtain
sarsrecov
donor
use
sar
protein
nonapeptid
deriv
dimerx
ig
fusion
protein
two
nonapeptid
correspond
sequenc
fragment
either
protein
sarscov
hong
kong
univers
scienc
technolog
nonapeptid
show
high
affin
molecul
databas
analysi
valid
bind
assay
pbmc
isol
blood
sampl
obtain
five
donor
recov
sar
august
donor
work
peke
univers
first
hospit
infect
sarscov
april
april
five
donor
femal
express
rang
age
year
old
two
agematch
femal
sarsrecov
donor
two
healthi
donor
act
control
donor
studi
detect
sarscov
antibodi
recov
donor
independ
express
perform
use
commerci
avail
elisa
kit
euroimmun
medizinisch
labordiagnostika
ag
tabl
donor
gave
inform
consent
collect
test
pbmc
sampl
protocol
approv
author
hospit
ethic
review
committe
elispot
assay
detect
ifngsecret
cell
perform
accord
method
describ
previous
briefli
pbmc
collect
donor
list
plate
triplic
roundbottom
plate
cell
incub
agml
either
nonapeptid
co
stimul
cell
thoroughli
mix
transfer
onto
flatbottom
nitrocellulos
plate
ha
multiscreen
millipor
bedford
usa
coat
antiifng
mab
agml
dilut
ph
carbon
buffer
cell
incub
addit
h
plate
wash
block
human
ab
serum
h
ifngsecret
spot
detect
use
commerci
kit
mabtech
sweden
accord
instruct
manufactur
color
spot
identifi
cytokineproduc
cell
count
use
dissect
microscop
mean
number
spot
triplic
well
calcul
express
number
specif
ifngsecret
cultur
pbmc
cell
dimerx
ig
fusion
protein
analysi
specif
cell
sar
viru
complex
sarscovspecif
nonapeptid
dimerx
ig
fusion
protein
gift
mr
zhang
jing
bd
bioscienc
usa
produc
modifi
activ
peptideload
acid
strip
follow
standard
protocol
describ
applic
handbook
edit
bd
bioscienc
briefli
nonapeptid
concentr
calcul
note
formula
dissolv
mgml
use
dmso
sigma
us
dilut
steril
pb
mgml
use
incub
bd
dimerx
reagent
expos
volum
equival
citratephosph
buffer
h
ph
mixtur
adjust
mixtur
incub
h
allow
protein
refold
pbmc
sar
patient
control
block
human
ab
serum
h
stain
cell
suspend
pb
concentr
approxim
million
cell
per
al
incub
ag
load
bd
dimerx
h
wash
al
pb
cell
resuspend
al
pb
contain
ag
fitclabel
antimous
igg
bd
bioscienc
us
incub
min
wash
twice
al
pb
cell
resuspend
al
pb
contain
ag
percpconjug
antihuman
min
wash
twice
pb
cell
resuspend
tabl
data
patient
studi
result
discuss
potent
immunogen
cell
epitop
protein
sarscov
viru
defin
previou
studi
nonapeptid
leu
val
posit
anchor
hlaa
peptid
bind
groov
show
similar
high
affin
molecul
cell
bind
assay
pbmc
sarsrecov
donor
specif
ctl
identifi
dimerx
stain
well
elispot
assay
use
nonapeptid
fig
furthermor
result
dimerx
stain
parallel
result
elispot
identifi
class
mhcrestrict
cell
respons
tabl
studi
pbmc
sarsrecov
donor
healthi
donor
also
assay
none
control
respond
either
assay
system
tabl
suggest
dimerx
ig
use
tool
screen
ctl
direct
specif
epitop
sarscov
protein
dimerx
stain
well
tetram
stain
provid
direct
method
use
flow
cytometri
identifi
specif
ctl
tetram
technolog
technic
difficult
produc
use
one
specif
peptid
contrast
dimerx
present
varieti
antigen
peptid
case
combin
thu
dimerxpeptid
complex
techniqu
easili
adopt
clinic
immunolog
lab
time
cours
antiviralspecif
ctl
identifi
techniqu
rel
short
follow
recoveri
viral
infect
minim
util
complex
technolog
tetram
requir
identifi
prepar
appropri
antigenspecif
epitop
contrast
dimerx
fusion
protein
method
stain
antigenspecif
c
ctl
appear
readili
adapt
method
detect
viralspecif
cell
postvir
recoveri
phase
method
could
prove
valuabl
understand
normal
immun
respons
sarscov
well
potenti
help
explain
vari
outcom
associ
sar
infect
pbmc
sarsrecov
donor
could
activ
secret
ifng
b
cell
detect
pbmc
sarsrecov
donor
